Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.68 |
| ▸ | RAF1 | P04049 | 2/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.68 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.68 |
| ▸ | NEK2 | P51955 | 2/20 | 0.68 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.68 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.68 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.68 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.68 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.68 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.68 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.68 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | PIR | O00625 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298039 | 0.86 | BRAF (0.74) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL29796856 | 0.86 | BRAF (0.74) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299832 | 0.86 | BRAF (0.68) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL288519 | 0.85 | CYP2C9 (0.60) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299436 | 0.85 | BRAF (0.69) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7744468 | 0.84 | BRAF (0.66) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL288590 | 0.84 | BRAF (0.65) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298696 | 0.83 | CYP2C9 (0.70) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL1821525 | 0.83 | CYP3A4 (0.64) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299672 | 0.83 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, PRKACA, RAF1 | BRAF 1/4885RIPK2 870/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.